Purdue Biologist Stanton B. Gelvin explained how Agrobacterium moves DNA into wounded plant cells, and why cracking that “black box” matters for agriculture during a seminar Wednesday afternoon at the ...
February 25, 2026 marks one year since KJ, an infant born with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, became the world's first person to receive a personalized CRISPR-based gene ...
The Food and Drug Administration on Monday laid out a new pathway aimed at spurring novel individualized treatments targeting ...
The framework, first introduced by FDA Commissioner Marty Makary and Center for Biologics Evaluation and Research head Vinay ...
After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, ...
One of the most promising is its cardiovascular disease therapy candidate CTX310, a single-treatment gene therapy that has ...
ADRIAN WOOLFSON, scientist and founder of Genyro, has authored a brave new book, 'On the Future of Species'. Here, Woolfson examines with SUCHETA DASGUPTA the future of humanity in a world of AI ...
Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
Some brain cells can resist the toxic processes associated with Alzheimer's disease and other forms of dementia. Scientists have now identified the "cellular hazmat team" that keeps neurons healthy.
CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.
Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.
A new CRISPR breakthrough shows scientists can turn genes back on without cutting DNA, by removing chemical tags that act like molecular anchors. The work confirms these tags actively silence genes, ...